These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 3881949)

  • 21. Aztreonam therapy for gram-negative pneumonia.
    Greenberg RN; Reilly PM; Luppen KL; Bollinger M; McMillian R
    Am J Med; 1985 Feb; 78(2A):31-3. PubMed ID: 3918444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aztreonam therapy for serious gram-negative bacillary infections.
    Cone LA; Woodard DR
    Rev Infect Dis; 1985; 7 Suppl 4():S794-802. PubMed ID: 3909339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Susceptibility of clinical isolates to aztreonam].
    Nagasawa Z; Nishimura T; Nagumo F; Ueda H; Tadano J; Katoh O; Yamada H
    Jpn J Antibiot; 1989 Jun; 42(6):1257-70. PubMed ID: 2507799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro antibacterial activity of a new parenteral penem, sulopenem].
    Yoshida T; Tateda E; Hiramatsu K; Yokota T
    Jpn J Antibiot; 1996 Apr; 49(4):324-37. PubMed ID: 8786624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microbiology and management of joint and bone infections due to anaerobic bacteria.
    Brook I
    J Orthop Sci; 2008 Mar; 13(2):160-9. PubMed ID: 18392922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of aztreonam in the treatment of skeletal infections due to Pseudomonas aeruginosa.
    Conrad DA; Williams RR; Couchman TL; Lentnek AL
    Rev Infect Dis; 1991; 13 Suppl 7():S634-9. PubMed ID: 2068473
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Use of aztreonam for the purpose of preventing postoperative purulent complications].
    Iakovlev VP; Khlebnikov EP; Vishnevskiĭ VA; Moroz VIu; Popov SV; Elagina LV
    Antibiot Khimioter; 1996 Feb; 41(2):40-2. PubMed ID: 8929118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of aztreonam in difficult-to-treat infections with prolonged posttreatment follow-up.
    Giamarellou H; Galanakis N; Douzinas E; Petrikkos G; El Messidi M; Papoulias G; Daikos GK
    Antimicrob Agents Chemother; 1984 Aug; 26(2):245-9. PubMed ID: 6541453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli.
    Nolen TM; Phillips HL; Hall HJ
    Rev Infect Dis; 1985; 7 Suppl 4():S666-8. PubMed ID: 3909321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pilot study of oral fleroxacin given once daily in patients with bone and joint infections.
    Putz PA
    Am J Med; 1993 Mar; 94(3A):177S-181S. PubMed ID: 8452177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates.
    Testa R; Cantón R; Giani T; Morosini MI; Nichols WW; Seifert H; Stefanik D; Rossolini GM; Nordmann P
    Int J Antimicrob Agents; 2015 Jun; 45(6):641-6. PubMed ID: 25748553
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral ciprofloxacin in the treatment of elderly patients with complicated urinary tract infections due to trimethoprim/sulfamethoxazole-resistant bacteria.
    Preheim LC; Cuevas TA; Roccaforte JS; Mellencamp MA; Bittner MJ
    Am J Med; 1987 Apr; 82(4A):295-300. PubMed ID: 3555051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of aztreonam in patients suffering from urinary tract infections with contraindications for the use of aminoglycosides.
    Fraschini F; Scaglione F; Alessandria M; Gattei G
    Chemioterapia; 1986 Oct; 5(5):319-21. PubMed ID: 3791478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical evaluation of cefoxitin in treatment of infections in 47 orthopedic patients.
    Schurman DJ; Dillingham M
    Rev Infect Dis; 1979; 1(1):206-9. PubMed ID: 318224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of skin, skin structure, bone, and joint infections with ceftazidime.
    Gentry LO
    Am J Med; 1985 Aug; 79(2A):67-74. PubMed ID: 3895921
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aztreonam--an overview.
    Hopefl AW
    Drug Intell Clin Pharm; 1985 Mar; 19(3):171-5. PubMed ID: 3884302
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of moxalactam with emphasis on infections due to multidrug-resistant organisms in patients with renal insufficiency.
    Trager GM; Panwalker AP; Malow JB; Porembski PE; Ramirez CA; Zar FA
    Chemotherapy; 1981; 27(4):287-95. PubMed ID: 6454542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of low dose aztreonam in the treatment of moderate to severe gram-negative bacterial infections.
    Clergeot A; Steru D; Rosset MA; Carbon C
    J Antimicrob Chemother; 1989 May; 23(5):753-8. PubMed ID: 2759924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-vitro activities of cefepime against Enterobacter cloacae, Serratia marcescens, Pseudomonas aeruginosa and other aerobic gram-negative bacilli.
    Chong Y; Lee K; Kwon OH
    J Antimicrob Chemother; 1993 Nov; 32 Suppl B():21-9. PubMed ID: 8150765
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effective and rapid presumptive identification of gram-negative bacilli in routine urine, pus, and stool cultures: evaluation of the use of CHROMagar orientation medium in conjunction with simple biochemical tests.
    Ohkusu K
    J Clin Microbiol; 2000 Dec; 38(12):4586-92. PubMed ID: 11101600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.